[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alcohol-abuse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alcohol-abuse":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,48,85,109,141,170,192,220,248,278,324,359,391,415,446,469,489,513,538,561,591],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053742","the-effect-of-comorbid-alcoholsubstance-use-100053742",false,"NCT07692984","The Effect of Comorbid Alcohol\u002FSubstance Use","The Effect of Comorbid Alcohol\u002FSubstance Use on Social Inclusion and Clinical Outcome in Individuals With Severe Mental Illness Enrolled in a Community Mental Health Center: A Cross-Sectional Case-Control Study","Inclusion Criteria:\n\n* Being 18 years of age or older,\n* Having a diagnosis of Schizophrenia Spectrum Disorder and Other Psychotic Disorders or Bipolar Disorder according to DSM-5 diagnostic criteria,\n* Being actively followed up at the TRSM for at least 6 months.\n\nExclusion Criteria:\n\n* Individuals diagnosed with organic brain damage or neurodevelopmental disorders (intellectual disability, etc.),\n* Individuals with severe cognitive impairment that prevents them from communicating adequately.","ALL","18 Years","65 Years",{"count":20,"type":21},297,"ESTIMATED","OBSERVATIONAL","Study Design This study was designed as a comparative, cross-sectional case-control study examining the effect of comorbid alcohol and substance use disorder (ASUD) on clinical course and social inclusion among individuals with severe mental illness followed at a Community Mental Health Center (CMHC). The study did not involve any interventions.\n\nAim The aim of this study is to examine the effect of comorbid alcohol and substance use on clinical course parameters-such as number of hospitalizations and medication dosages-and on social inclusion indicators-such as employment, social participation, and social adjustment-among individuals with severe mental illness followed at the CMHC, in comparison with a matched control group without substance use.\n\nResearch Questions\n\nWhat are the rates of comorbid alcohol and substance use among patients with severe mental illness followed at the CMHC? What are the current addiction symptoms, number of hospitalizations, and employment rates among individuals with severe mental illness and comorbid ASUD? What is the level of continuity of CMHC engagement and social participation among individuals with severe mental illness and comorbid ASUD, and what factors influence it? How does the level of social inclusion among individuals with severe mental illness and comorbid ASUD compare with that of individuals without ASUD?\n\nHypotheses\n\nH1: The average annual number of hospitalizations among individuals with a dual diagnosis (severe mental illness + ASUD) followed at the CMHC is significantly higher than among those without substance use.\n\nH2: Among individuals with a dual diagnosis, the daily medication doses (e.g., chlorpromazine equivalents) required to control psychotic or manic symptoms are higher than in the control group.\n\nH3: Social inclusion is lower among patients with substance use compared with the control group.\n\nH4: Employment rates among individuals with a dual diagnosis are significantly lower than among those with severe mental illness alone.\n\nH5: Substance use negatively affects patients' social participation, including involvement in activities and friendships.\n\nH6: Attendance rates at CMHC workshops and rehabilitation programs are lower among individuals with substance use compared with the control group.",[25,26,27,28,29,30,31],"Alcohol Abuse","Alcohol Use Disorder","Substance Use Disorders","Severe Mental Disorder","Schizophrenia","Bipolar Disorder","Ostracism",[33,27,28,34],"alcohol use disorder","ostracism","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2026-06-20",{"date":43,"type":21},"2026-12-30",{"name":45,"class":46},"Abant Izzet Baysal University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100609614","safety-and-effectiveness-of-the-brainsway-deep-transcranial-magnetic-stimulation-deep-tms-for-treatment-of-alcohol-use-disorder-aud-100609614","NCT07216872","Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)","A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)","Inclusion Criteria:\n\n1. Male or female subjects, 18-86 years old.\n2. Subjects diagnosed with AUD and who meet criteria for moderate (4-5 out of the 12 symptoms) to severe (\\> 6 out of the 12 symptoms) AUD according to the DSM-5 diagnostic criteria as determined by a licensed clinician according to the DSM-5 criteria, and verified with the Mini International Neuropsychiatric Interview (Standard MINI version 7.0.2).\n3. Subjects who have a history of at least 24 heavy drinking days during the 90 days prior to screening (average \\>=8 HDD\u002Fmonth), based on TLFB).\n4. Treatment seeking individuals with a treatment goal of achieving abstinence or reducing heavy drinking.\n5. Subjects able to understand and provide signed informed consent, and able to adhere to the requirements and restrictions of this protocol.\n6. Satisfactory answers on safety screening questionnaire for transcranial magnetic stimulation.\n\nExclusion Criteria:\n\n1. Subjects diagnosed with schizophrenia or chronic psychotic disorder as determined by a licensed clinician according to the DSM-5 criteria, and verified with the Mini International Neuropsychiatric Interview (Standard MINI version 7.0.2).\n2. Subjects with present suicidal risk as assessed by the investigator or significant suicide risk based on MADRS item 10 score of 4 or 6, or a history of attempted suicide in the last year.\n3. Subjects who initiated treatment with any of the following medications which are known to effect alcohol consumption, within 30 days of the Screening visit: acamprosate, baclofen, buprenorphine, disulfiram, gabapentin, naltrexone, topiramate and varenicline.\n4. Subjects with a significant medical illness that is not well controlled (e.g., hepatic impairment, diabetes, hypertension, heart disease, septicemia, active tuberculosis, progressive neoplasm, frequent and severe migraine headaches, etc.).\n5. Subjects experiencing acute alcohol withdrawal. This will be determined using the Clinical Institute Withdrawal Assessment of Alcohol - revised (CIWA-Ar) wherein subjects with a value of \\>7 will not be permitted to receive TMS on that day to mitigate any potential risk of a seizure. Treatments may be rescheduled and CIWA-AR and alcohol breath tests may be reassessed, although if more than the allowed treatment sessions are missed, the subject will be withdrawn from the study.\n6. Subjects with a history of epilepsy or seizure (not including history of alcohol withdrawal seizure, ECT induced seizures, or childhood febrile seizures).\n7. Individuals with a first-degree relative family history of seizure.\n8. Subjects with a high risk for severe violence or suicidality as assessed during the screening interview.\n9. Conductive, ferromagnetic or other magnetic-sensitive metals implanted in the head (outside the mouth) or within 10 cm of the treatment coil (e.g., cochlear implants, implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, bullet fragments, shrapnel, surgical clips, fragments from welding or metal work).\n10. Subjects with cardiac pacemakers or active implantable electrodes\u002Fneurostimulators within 30 cm of the treatment coil.\n11. Subjects with a significant neurological disorder or insult including, but not limited to:\n\n    * Any condition likely to be associated with increased intracranial pressure\n    * Space occupying brain lesion\n    * History of cerebrovascular accident\n    * Transient ischemic attack within two years\n    * Cerebral aneurysm\n    * Dementia\n    * Mini Mental State Exam score of less than or equal to 24\n    * Parkinson's disease\n    * Huntington's chorea\n    * Multiple sclerosis\n12. Subjects suffering from significant hearing loss.\n13. Previous treatment with TMS within one year.\n14. Participation in another clinical investigation in which a device or drug has been used within 4 weeks of screening.\n15. If participating in psychotherapy, subject is not in stable treatment for at least 3 months prior to entry into the study or anticipates a change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the rTMS trial.\n16. Known or suspected pregnancy or lactation or planning to become pregnant.\n17. Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.","86 Years",{"count":57,"type":21},186,"INTERVENTIONAL",[60],"NA","The study will compare alcohol use in two groups of subjects. One group will be assigned to the Deep TMS treatment and the other group will be assigned to the sham treatment. This is a prospective, 6-month, double blind, randomized, controlled, multi-center trial in outpatients recruited in both academic and private research centers. The study population will consist of subjects diagnosed with moderate to severe AUD. The study is comprised of three phases:\n\n1. Pre-study Screening and Baseline Phase\n2. Acute Treatment Phase and\n3. Maintenance Treatment and Follow up Phase\n\nSubjects of all ethnic and gender categories, ages ranging between 18-86 years will be screened for study eligibility according to the inclusion and exclusion criteria. Subjects who meet the eligibility criteria and are willing to sign an informed consent form will be enrolled in the study. The subjects' demographic and baseline characteristics, as well as their overall medical condition will be assessed prior to treatment administration.\n\nEligible patients will be randomized with a 1:1 ratio to one of two study groups (treatment or sham) and stratified by site. Randomization will be employed to avoid bias in the assignment of subjects to treatment group. All subjects will undergo the same treatment regimen, regardless of the assigned treatment group. The acute treatment phase will include 15 treatment visits over a period of 3-5 weeks.\n\nThe Maintenance Treatment \\& Follow-up phase will include one treatment visit per week from the end of the Acute Treatment Phase until the 6 month follow-up visit.\n\nAt each treatment session, prior to stimulation onset, alcohol related cues will be presented to the subject. After the offset of the alcohol cue presentation, active or sham Deep TMS stimulation will be administered.\n\nThe study design is directed towards a comparison between active treatment and sham, up to 4 months and 6 months follow-up. Efficacy will be assessed using the primary efficacy measure of the percent heavy drinking days during months 2-4, based on the Time Line Follow Back (TLFB) reporting. Additionally, several subject assessment scales will be used during the course of the study to assess alcohol use and alcohol craving.\n\nSafety will be assessed, including monitoring the severity, causality and frequency of all adverse events, vital signs, and physical and neurological examination.",[26,63,25,64,65,66],"Alcoholism","Alcohol Dependence","Alcohol Abuse\u002FDependence","Alcohol Addiction",[33,68,69,70,71,72,73,74],"alcoholism","alcohol abuse","alcohol dependence","alcohol addiction","DTMS","rfTMS","Brainsway","2026-06-18",{"date":77,"type":39},"2026-06-22",{"date":79,"type":39},"2025-11-07",{"date":81,"type":21},"2027-12-01",{"name":74,"class":83},"INDUSTRY",9,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":58,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":47},"100496397","adaptation-and-evaluation-of-bright-horizons-100496397","NCT05743699","Adaptation and Evaluation of Bright Horizons","Adaptation and Evaluation of Bright Horizons: An Evidence Based Intervention for Prevention of Binge Drinking and Drug Use","Inclusion Criteria:\n\n* Aged 10-24\n* Confirmed binge alcohol use event reported to the surveillance system within 90 days\n* Self identify as Native American\n* Reside on or near the Fort Apache Indian Reservation\n* Have parental or legal guardian consent\u002Fprovide youth assent\n\nExclusion Criteria:\n\n* Unstable and severe medical, psychiatric or drug use problems that necessitates inpatient treatment\n* Acute suicidal or homicidal ideation requiring immediate intervention\n* Recent and severe stressful life events such as physical or sexual abuse, or violent crime victimization that requires specific and high intensity interventions or out of home placement\n* Doesn't speak English\n* Severally visually impaired","10 Years","24 Years",{"count":95,"type":21},100,[60],"This study will test if a program called 'Bright Horizons' is effective at reducing binge substance use among adolescents.\n\nBright Horizons is a culturally adapted intervention developed and tested through a partnership between The White Mountain Apache Tribe and Johns Hopkins University. Bright Horizons is a brief intervention that teaches emotion regulation, coping skills, and problem solving. The intervention also uses goal setting to reduce alcohol and other substance use and to connect to individuals with treatment.",[25,99],"Substance Use","2026-06-05",{"date":102,"type":39},"2026-06-09",{"date":104,"type":39},"2025-07-17",{"date":106,"type":21},"2027-01-31",{"name":108,"class":46},"Johns Hopkins Bloomberg School of Public Health",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":58,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":47},"100614566","tan-for-substance-use-disorder-100614566","NCT07281261","tAN for Substance Use Disorder","Study of Transcutaneous Auricular Neurostimulation as a Treatment for Substance Use Disorder","Inclusion Criteria:\n\n1. Male or female (evenly recruited) aged 18-64 years old\n2. Meeting DSM-5 criteria of moderate or above AUD at screening using the structured clinical interview for DSM-5 (SCID-5)\n3. Demonstration of at least moderate risk of alcohol use at screening using the WHO-ASSIST\n4. Demonstration of high risk for moderate to severe alcohol withdrawal syndrome (Prediction of Alcohol Withdrawal Severity Scale \\[PAWSS\\] \\> 4 at admission)\n5. Demonstration of severe withdrawal symptoms (Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised \\[CIWA-Ar\\] ≥ 8 at screening)\n6. Positive urine test for alcohol at screening\n7. Be able to provide written informed consent\n8. Female subjects must be non-nursing and not pregnant\n9. Meet the MRI safety screening form provided by the Center for Advanced MR Imaging (CAMRI) at BCM.\n\nExclusion Criteria:\n\n1. In the opinion of the clinician and the research team at admission, be expected to fail to complete the study protocol due to probably relocation from The Menninger Clinic area or not tolerable to receive tAN\n2. Current use of tobacco\n3. Is pregnant or nursing\n4. Contraindications to MRI (pacemaker, cochlear implants, metal in eyes, other metal implants, etc.)\n5. Do not meet the pre-screening MRI questions provided by the Center for Advanced MR Imaging (CAMRI) at BCM","64 Years",{"count":118,"type":21},20,[60],"The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity (RSFC) between OFC and striatum in patients with alcohol use disorder (AUD). Enrolled participants will wear the tAN device on-site (at The Menninger Clinic) for the 5-day detox treatment period. Participants with AUD will be single-blinded randomized into 2 groups - a treatment group (active tAN) and a placebo group (sham tAN). Each group will consist of five separate time points - admission, screening, baseline, tAN treatment, and post tAN treatment. Clinical measures collected before, during, and after treatment will include alcohol withdrawal severity, craving, benzodiazepine usage, and assessments of depression and suicidal behaviors. Participants will undergo MRI scans before and after the treatment period to assess changes in brain connectivity and their relationship to clinical outcomes.",[26,25,27,122],"Substance Use Disorders Alcohol Use Withdrawal State",[124,26,125,126,127,128,129,130,131],"Alcohol","Substance Use Disorder","Transcutaneous Auricular Neurostimulation","tAN","Neurostimulation","Vagus Nerve Stimulation","Auricular Neurostimulation","Transcutaneous","2026-06-01",{"date":134,"type":39},"2026-06-02",{"date":136,"type":39},"2026-01-28",{"date":138,"type":21},"2026-08-31",{"name":140,"class":83},"Spark Biomedical, Inc.",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":149,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":58,"phases":152,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":47},"100575404","reducing-hazardous-alcohol-use-and-optimizing-treatment-as-prevention-among-men-living-with-hiv-in-risk-environments-100575404","NCT06771843","Reducing Hazardous Alcohol Use and Optimizing Treatment as Prevention Among Men Living With HIV in Risk Environments","Kisoboka: Reducing Hazardous Alcohol Use and Optimizing Treatment as Prevention Among Men Living With HIV in Risk Environments","Kisoboka","Inclusion Criteria:\n\n1. living with HIV;\n2. residing in a fishing community (on most days\u002Fnights);\n3. AUDIT-C positive (≥4) indicating potential hazardous drinking;\n4. \\>6 months since initial antiretroviral treatment (ART) initiation;\n5. not planning to move from the area within the next 6 months;\n6. have their own mobile phone and can be reached via phone.\n7. an indicator of potential suboptimal treatment as prevention (TasP) either:\n\n(i) last HIV viral load test (within 6 months) was detectable (\\>20) or (ii) last viral load test between 6 and 13 months ago was detectable (\\>20) and reports missing ≥2 ART doses in the past 2 weeks or (iii) a lack of viral load test results for the prior 13 months in clinic records and reports missing ≥2 ART doses in the past 2 weeks;\n\nExclusion Criteria:\n\n1. visibly intoxicated at enrollment (eligible to enroll when not intoxicated);\n2. does not speak Luganda or English;\n3. currently receiving a majority of work payments via mobile money\u002Fdigital payments;\n4. participated in the Kisoboka pilot RCT;\n5. unable to read basic Luganda or English","MALE",{"count":151,"type":21},716,[60],"The investigators developed the Kisoboka (\"It is possible\") Intervention to address limitations of existing evidence-based interventions to optimize treatment as prevention among men living with HIV who drink alcohol at hazardous levels in \"risk environments\" such as fishing communities through reductions in hazardous alcohol use, improved adherence to HIV medications and achieving undetectable HIV viral loads.\n\nSocial and structural determinants unique to fishing communities interact to create a risk environment where hazardous drinking impedes adherence to HIV medications among men living with HIV, including prevalent social norms of drinking, drinking as a way of experiencing \"reward\" and connecting with others (e.g. in the context of transactional sex), stressful work conditions, a \"live for today\" outlook, and a cash-based economy with no traditional savings infrastructure leading to ease of daily expenditure on drinking and sex work. These social and environmental conditions result in high levels of alcohol misuse and HIV risk, poor HIV outcomes, and exacerbation of HIV-associated wellness comorbidities such as poor mental and subjective physical health and food insecurity.\n\nThe goal of this study is to learn if the intervention called Kisoboka works to help men in fishing communities reduce hazardous alcohol use, be better able to take the participants HIV medication as prescribed, and have undetectable HIV viral loads. The investigators will compare the Kisoboka intervention to a brief alcohol screening, adherence counseling, and referrals, and to components of the Kisoboka intervention.\n\nParticipants will attend intervention counseling sessions according to the study arm to which the participants are randomly assigned. The number of sessions ranges from 1 to 6 over 1 to 16 weeks and are individual only or both individual and group sessions.",[155,25,156,26,157],"HIV Antiretroviral Therapy (ART) Adherence","HIV Infection","HIV Infections",[159,160],"behavioral economics","motivational interviewing","2026-05-11",{"date":163,"type":39},"2026-05-12",{"date":165,"type":39},"2025-06-16",{"date":167,"type":21},"2029-02",{"name":169,"class":46},"San Diego State University",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":177,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":58,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":47},"100544320","an-economic-and-relationship-strengthening-intervention-to-reduce-alcohol-use-in-malawi-100544320","NCT06367348","An Economic and Relationship-strengthening Intervention to Reduce Alcohol Use in Malawi","Mlambe: A Randomized Controlled Trial of an Economic and Relationship-Strengthening Intervention to Reduce Alcohol Use in Malawi","Inclusion Criteria:\n\n1. In a married or cohabitating union\n2. Have at least one partner with a positive AUDIT-C screen in prior 3 months\n3. Must also currently be on ART for at least 6 months\n4. Must have disclosed their HIV status to their partner\n\nExclusion Criteria:\n\n1\\) Severe intimate partner violence reported in previous 3 months and\u002For fear that safety would be at risk by participation in the study (reported at screening). Couples who participated in Mlambe's pilot study will also be excluded.",true,{"count":179,"type":21},500,[60],"With a full-scale randomized control trial, the investigators will evaluate the efficacy and cost effectiveness of Mlambe, an economic and relationship-strengthening intervention that provides incentivized saving accounts, financial literacy training, and relationship skills education to break the cycle of poverty around drinking, strengthen couple support and communication, and reduce heavy drinking among HIV-affected married couples with a partner who drinks alcohol in Malawi.",[183,25],"HIV\u002FAIDS",{"date":185,"type":39},"2026-05-14",{"date":187,"type":39},"2025-02-14",{"date":189,"type":21},"2028-05",{"name":191,"class":46},"University of California, San Francisco",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":177,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":58,"phases":200,"briefSummary":201,"conditions":202,"keywords":206,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":47},"100486831","a-smart-evaluation-of-an-adaptive-web-based-aud-treatment-for-service-members-and-their-partners-100486831","NCT05619185","A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners","Inclusion Criteria:\n\n* at least 18 years of age;\n* be living together with their partner, with no plans to change that status in the next 2 months;\n* not be in the military themselves (to reduce concerns about mandated reporting of alcohol use);\n* score ≥4 on the AUDIT-C for females or ≥5 for males\u002Fother;\n* respond yes to \"Do you feel safe in your current relationship?\" from the Partner Violence Screen;\n* report not currently being in mental health or alcohol treatment (CP and SM)\n* understand English fluently,\n* be willing to try an online program to address risky drinking.\n\nWe require cohabitating CPs and SMs with no anticipated changes in the next two months to ensure close contact and opportunity to practice new skills, and those who would feel safe participating.\n\nExclusion Criteria:\n\n* CPs in substance use treatment or their SM was in treatment in the last three months;\n* does not feel safe in the current relationship;\n* does not understand English fluently;\n* has an impaired capacity (cognitive, visual, or hearing);\n* is not cohabitating with their SM",{"count":199,"type":21},744,[60],"The purpose of this study is to evaluate the efficacy of an adaptive web intervention (Partners Connect) on military spouse drinking behaviors (CPs) and service member help-seeking (SMs). The investigators want to identify for whom this intervention is most efficacious and on what drinking behaviors and mechanisms. The investigators hypothesize that the intervention will reduce concerned partner drinking and increase service member help-seeking, compared to website resources, and that phone-based CRAFT will increase help-seeking behaviors, compared to those who are guided via a CRAFT workbook.",[25,26,203,204,205],"Alcohol Drinking","Relations, Interpersonal","Military Family",[207,208,209,210],"military","alcohol","drinking","substance use","2026-04-22",{"date":213,"type":39},"2026-04-27",{"date":215,"type":39},"2024-06-14",{"date":217,"type":21},"2027-08-31",{"name":219,"class":46},"Stanford University",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":18,"enrollmentInfo":229,"targetDuration":4,"studyType":58,"phases":231,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":47},"100547256","phase-2-psilocybin-or-ketamine-for-alcohol-use-disorder-an-active-comparator-trial-100547256","NCT06405607","Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial","Psilocybin vs Ketamine for Alcohol Use Disorder","Psi or Ket","Inclusion criteria:\n\n* Weight between 50kg and 150kg\n* No known allergies to rescue medication\n* For people capable of becoming pregnant, not pregnant and using contraception\n* Not currently breastfeeding\n* Meets criteria for DSM-V moderate to severe AUD.\n* Have at least 4 heavy drinking days (5 or more standard drinks in a day) in the past 30 days.\n* Not currently participating in formal treatment for AUD.\n* No history of a of cerebrovascular accident, asthma, or significant alcohol withdrawal history\n* No seizure disorder, coronary artery disease, heart failure, uncontrolled hypertension, insulin-dependent diabetes, pancreatitis, liver disease\n* No hallucinogen or ketamine use in past 12 months\n* No self-reported, personal, or familial history of specific psychotic disorders\u002Fepisodes.\n* No serious traumatic brain injury (TBI) in the past 2 years\n* No substance use disorder other than AUD over the past 12 months\n* If taking a GLP-1 agonist, stable dosage for past 3 months\n* Family member\u002Ffriend for pick-up, overnight post-drug session monitoring.\n* No MRI contraindications\n\nExclusion Criteria:\n\nDrug\u002Fmedication assessment that yields: nonprescription medication use, nutritional supplement, or herbal supplement (except when approved by the study investigators), medically unstable, current medication use that has significant potential to interact with study drug (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants, or benzodiazepines).\n\nPsychiatric assessment that yields:1) history of severe suicide attempt, 2) current suicidality 3) first-degree relative with schizophrenia or schizoaffective disorder, 4) comorbid substance use disorder including cocaine, psychostimulant, or opioid use disorder within past 12 months 5) history of co-occurring psychotic episode\u002Fdiagnosis including schizophrenia, schizoaffective disorder, schizophreniform, substance-induced psychosis, delusional disorder, or psychosis not otherwise specified, 6) high risk of adverse emotional or behavioral reaction based on the medical monitor's clinical evaluation that may also yield evidence of serious current stressors, a lack of meaningful social support, antisocial behavior, and\u002For serious personality disorders amongst other conditions.\n\nMedical assessment that yields: serious ECG abnormalities (evidence of ischemia, myocardial infarction, QTc prolongation \\[QTc \\> .045\\]), serious abnormalities of complete blood count or chemistries, medical conditions that would preclude safe participation (significantly impaired liver function), or pregnancy.\n\nMRI contraindication (pacemaker, etc.)","21 Years",{"count":230,"type":21},80,[232],"PHASE2","This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg\u002Fkg dose of ketamine.",[26,64,25],[236,237,238],"psychedelic","psilocybin","ketamine","2025-11-21",{"date":241,"type":39},"2025-11-28",{"date":243,"type":39},"2025-06-12",{"date":245,"type":21},"2028-04",{"name":247,"class":46},"University of Iowa",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":254,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":58,"phases":258,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":47},"100548033","developing-functional-connectivity-guided-tms-for-alcohol-use-disorder-100548033","NCT06415721","Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder","Inclusion Criteria:\n\n* Between age 25 and 75.\n* Current DSM-5 diagnosis of moderate to severe AUD (≥4 diagnostic symptoms).\n* Able to attend scheduled clinic visits\n* Able to read, understand and voluntarily sign Informed Consent prior to participating in any study-specific procedures or assessments.\n* If on a medication regimen, that regimen will be stable for the duration of the study;\n* Fluency in English.\n\nExclusion Criteria:\n\n* Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, metal in the head, metal in the body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device\u002Fobjected in the head and body within 30 cm of the treatment coil.\n* General medical condition, disease or neurological disorder that interferes with the assessments or participation.\n* Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.\n* Current substance abuse (except caffeine or nicotine) as determined by positive toxicology screen.\n* Have a mass lesion, cerebral infarct, or other active CNS disease, including an alcohol-related seizure or a seizure disorder. • A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study.\n* Severe impediment to vision, hearing and\u002For hand movement, likely to interfere with the ability to follow study protocols. • Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness).\n* Taking benzodiazepine or neuroleptic medications, or any medication known to alter seizure threshold\n* unstable chronic illness.\n* Current or lifetime history of bipolar disorder or psychosis.\n* Participation in another concurrent intervention based clinical trial.","25 Years","75 Years",{"count":257,"type":21},40,[60],"Alcohol Use Disorders are currently positioned as the third leading cause of preventable death in the United States, constituting a humanitarian crisis with substantial financial burden on society and medical facilities. While several pharmacological interventions exist, 60% of individuals who seek these treatments relapse to alcohol within 6 months. These high relapse rates are due in part to elevated brain response to alcohol cues in the environment. This study seeks to evaluate the efficacy of one session of functional Magnetic Resonance Imaging (fMRI) guided transcranial magnetic stimulation (TMS) as a strategy to reduce brain reactivity to alcohol cues.",[26,25,63,261,262],"Drinking Behavior","Drinking Problem",[264,265,266,267],"Transcranial Magnetic Stimulation","Veterans","Neuroimaging","Relapse","2025-08-07",{"date":270,"type":39},"2025-08-13",{"date":272,"type":21},"2025-08-25",{"date":274,"type":21},"2026-01-01",{"name":276,"class":277},"VA Palo Alto Health Care System","FED",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":58,"phases":288,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":47},"100536490","virtual-incentive-treatment-for-alcohol-100536490","NCT06265506","Virtual Incentive Treatment for Alcohol","Assessing the Clinical and Cost-Effectiveness of a Virtual PEth-based Contingency Management for Adults With AUD","VITA","Inclusion Criteria:\n\n1. Had 2 heavy drinking episodes (assigned male at birth \\> 4 standard drinks (SDs), assigned female at birth \\> 3 SDs) or ≥14 SDs in the prior 14 days verified by PEth 16:0\u002F18:1 biomarker \\> 20 ng\u002FmL (indicates at least 2 heavy drinking episodes in past two weeks);\n2. Have a DSM-5 diagnosis of a current AUD as assessed by the Structured Clinical Interview for DSM-5;\n3. 18+ (individuals over 65 will be assessed for cognitive impairments)\n4. Are not receiving treatment for AUD\n5. Are able to complete virtual study visits via Zoom\n\nExclusion Criteria:\n\n1. have a current diagnosis of severe substance use disorder (other than AUD, tobacco, and cannabis);\n2. PEth biomarker ≤ 20 ng\u002FmL (indicates no heavy drinking in past month)\n3. inability to provide informed consent based on the UBACC or MacCAT-CR;\n4. alcohol withdrawal-related seizure or hospitalization in prior 12 months;\n5. psychiatrically or medically unsafe to participate, as assessed by the PI; and\u002For\n6. currently enrolled in alcohol treatment or another alcohol treatment study.",{"count":287,"type":21},200,[60],"The overall objective of this program of research is to utilize phosphatidylethanol (PEth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week CM intervention. This study will test a telehealth PEth-based CM model in a sample of adults with AUD (n=200), recruited via online platforms by randomizing individuals to six months of 1) an online cognitive behavioral therapy for AUD (CBT4CBT) and telehealth PEth-based CM (CM condition) or 2) CBT4CBT and reinforcers for submitting blood samples (no abstinence required) (control condition). Investigators will assess group differences in PEth-defined abstinence and regular excessive drinking (PEth \\>= 200 ng\u002FmL), and alcohol-related harms (e.g., smoking, drug use). This study will address important gaps in CM research by assessing outcomes during a 12-month follow-up, which is much longer than most previous CM studies; using a conceptual model to identify predictors of post-treatment abstinence. Investigators will conduct an economic analysis to place the cost of this model in the context of downstream CM-associated cost-offsets and improvements in personal and public health.",[26,203,25,64],[292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314],"Contingency Management","Alcohol Abstinence","Adult","Biological Markers","Blood","Clinical effectiveness","Cognitive Therapy","Blood collection","Ethyl glucuronide","Health Care Costs","Heavy Drinking","Addictions Neuroclinical Assessment","Cognition","Incentives","Phosphatidylethanol","Incentive salience","Anhedonia","Longitudinal Studies","Prediction of Response to Therapy","Randomized Clinical Trial","Telehealth","Virtual Health","Video conference","2025-05-23",{"date":317,"type":39},"2025-05-30",{"date":319,"type":39},"2024-06-18",{"date":321,"type":21},"2028-04-04",{"name":323,"class":46},"Washington State University",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":177,"sex":16,"minAge":331,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":58,"phases":335,"briefSummary":336,"conditions":337,"keywords":344,"overallStatus":349,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100584805","team-based-learning-intervention-to-prevent-risk-factors-for-chronic-diseases---a-cluster-randomized-trial-100584805","NCT06894134","Team-based Learning Intervention to Prevent Risk Factors for Chronic Diseases - a Cluster Randomized Trial","Team-based Learning Intervention in Adolescents to Prevent Risk Factors for Chronic Diseasers - a Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* Adolescent students of high school\n* Age ranging from 15 to 19 years old.\n\nExclusion Criteria:\n\n* Cognitive limitations\n* Physical limitations\n* Communication limitations\n* Use of medications that interfere with eating, physical activity, or sleeping habits.","15 Years","19 Years",{"count":334,"type":21},240,[60],"Background: Chronic diseases, such as cardiovascular diseases, diabetes, and cancer, are a major global health issue. Their modifiable risk factors, including poor diet, physical inactivity, irregular sleep, tobacco use, and excessive alcohol consumption, often emerge during adolescence and persist into adulthood. Early educational interventions can promote healthy habits and reduce their prevalence. Team-Based Learning (TBL), an active teaching method, has demonstrated effectiveness in improving knowledge and behaviors essential for a healthy lifestyle. Objective: evaluate whether a TBL-based educational intervention can improve adolescents' knowledge and habits related to chronic disease risk factors. Methods: A cluster randomized controlled trial (cRCT) will be conducted in public schools in Palmares, Brazil, targeting high school students aged 15-19 years. Fourteen schools will be randomly assigned to intervention and control groups. The intervention, consisting of four TBL modules, will cover healthy eating, physical activity, screen time, sleep, tobacco, and alcohol use, delivered by graduate nursing students under faculty supervision. Data collection will take place at three time points: pre-intervention, post-intervention, and three months later. The control group will continue receiving standard health education. Primary outcomes will assess behavioral changes, while secondary outcomes will analyze body mass index (BMI) and blood pressure. Analysis: Data will be analyzed using SPSS, with descriptive statistics, paired and unpaired t-tests, ANOVA, and chi-square tests. The analysis will account for clustering and be conducted using intention-to-treat analysis. Statistical significance will be set at p\\\u003C0.05. Conclusion: The study will provide evidence on TBL as a scalable tool for preventing risk factors in adolescents, contributing to long-term public health benefits.",[338,339,340,341,25,342,343],"Cardiovascular Diseases","Obesity Prevention","Sedentary Behaviors","Sleep Perception","Drug Abuse","Physical Inactivity",[345,346,347,348],"team-based learning","adolescents","prevention","chronic diseases","NOT_YET_RECRUITING","2025-03-25",{"date":352,"type":39},"2025-03-30",{"date":354,"type":21},"2025-09-01",{"date":356,"type":21},"2026-11-30",{"name":358,"class":46},"Professor Fernando Figueira Integral Medicine Institute",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":367,"targetDuration":4,"studyType":58,"phases":369,"briefSummary":370,"conditions":371,"keywords":375,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":47},"100535090","using-neurofeedback-to-understand-the-relationship-between-stress-and-alcohol-consumption-100535090","NCT06247306","Using Neurofeedback to Understand the Relationship Between Stress and Alcohol Consumption","Probing the Influence of Neural Stress Responses on Problematic Alcohol Use With Real-time fMRI Neurofeedback (C04)","NeuStress","Inclusion Criteria:\n\n* Age 18-65 years\n* Presence of 2 to a maximum of 5 criteria for alcohol use disorder according to DSM-5\n* no clinical necessity for detoxification treatment\n* participants may have a moderate cannabis use disorder and tobacco use disorder\n* Capacity for consent and ability to use self-assessment scales\n* Sufficient knowledge of German\n* Willingness to use a mobile phone with Android operating system\n\nExclusion Criteria:\n\n* Lifetime diagnosis of bipolar or psychotic disorder or a substance use disorder according to Diagnostical and Statistical Manual of Mental Disorders - 5 (DSM-5) that is not alcohol, cannabis, or tobacco use disorder\n* Current substance use other than cannabis and tobacco\n* Current diagnosis of one of the following conditions according to DSM-5: (hypo)manic episode, major depression, generalized anxiety disorder, post-traumatic stress disorder, borderline personality disorder, or obsessive-compulsive disorder\n* History of severe head trauma or other severe central neurological disorders (dementia, Parkinson\\'s disease, multiple sclerosis)\n* Pregnancy or lactation\n* Use of medications known to interact with the central nervous system within the last 10 days; testing at least four half-lives after the last dose\n* Exercising the prerogative of the \\"Right not to know\\" in the context of incidental findings during an examination or investigation",{"count":368,"type":21},102,[60],"In this research project, the aim is to discover the role specific brain networks play in the relationship between stress reactions and the desire for alcohol and alcohol consumption. To investigate this question, various brain imaging methods as well as cognitive tasks are combined. Various questionnaires are sampled and brain scans are conducted.\n\nIndividuals interested in participating in the study have to fulfill certain criteria...\n\n* no serious medical or mental health diagnosis\n* problematic alcohol drinking habits\n* interested in improving drinking habits\n\n  ...and undergo various non-invasive procedures\n* filling out several questionnaires concerning personality and habits\n* undergoing a mental performance task while being in a brain scanner (MRI)\n* attempting to regulate their own brain activity while lying in the MRI scanner\n* filling out an electronic diary for 6 weeks - concerning daily mood, stress, and alcohol habits\n\nParticipants will be randomly allocated to either one of 2 experimental groups. Both groups undergo the same tasks, receive the same instructions and only differ regarding some aspects of the brain self-regulation task .",[25,372,373,374],"Craving","Psychosocial Stressor","Neural Stress Response",[376,377,378,379,380,381],"functional Magnetic Resonance Imaging (fMRI)","psychosocial stress","real-time fMRI neurofeedback (rtfMRI neurofeedback)","problematic alcohol use","cortisol","Ecological momentary assessment (EMA)","2025-01-22",{"date":384,"type":39},"2025-01-23",{"date":386,"type":39},"2024-03-01",{"date":388,"type":21},"2027-07-01",{"name":390,"class":46},"Central Institute of Mental Health, Mannheim",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":58,"phases":401,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":47},"100437077","phase-2-efficacy-of-simvastatin-in-alcoholic-liver-fibrosis-100437077","NCT04971577","Efficacy of Simvastatin in Alcoholic Liver Fibrosis","Efficacy of Simvastatin in Reducing Liver Fibrosis in Patients With Advanced Fibrosis Due to Alcohol: Randomized, Double-blind, Placebo-controlled Clinical Trial","SIMFIB","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Chronic alcohol-related liver disease according to international guidelines (EASL, European Association for the Study of the Liver) and with data of significant liver fibrosis obtained in the diagnostic biopsy at the beginning of the study or in the last biopsy of the patient within 6 months prior to randomization. Significant liver fibrosis is defined by a score on the Ishak fibrosis scale of between 3 and 6.\n3. Patients in the compensated chronic liver disease phase defined by the absence of clinical decompensations at the time of entering the study, with or without data of portal hypertension.\n4. Women of childbearing potential must have a negative urine pregnancy test prior to study enrollment and agree to use highly effective contraceptive methods (combined oral pill, injectable or implanted contraceptive, intrauterine device \u002F hormone delivery system intrauterine) during the study.\n\nExclusion Criteria:\n\n1. Patients receiving statins or fibrates.\n2. Patients with other etiologies of liver disease in addition to alcohol: hepatitis C, hepatitis B, autoimmune hepatitis, Wilson's disease, or hemochromatosis.\n3. Patients in whom hepatitis C has been cured with antivirals in the 2 years prior to inclusion in the study.\n4. Patients with a CK elevation of 50% or more above the upper limit of normal at the time of study inclusion.\n5. Gastrointestinal bleeding due to portal hypertension within 12 months prior to inclusion in the study.\n6. Clinical hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy, in the 12 months prior to inclusion in the study.\n7. Patients in need of diuretic treatment in the previous 12 months to control ascites or hydrothorax.\n8. Spontaneous bacterial peritonitis within 12 months prior to study enrollment.\n9. Hepatocellular carcinoma of any stage.\n10. Patients with known muscle disease.\n11. Patients with previous rhabdomyolysis.\n12. Patients being treated with strong CYP3A4 enzyme inhibitors (see section 5.2: Concomitant drugs, not allowed and allowed).\n13. Patients being treated with drugs with possible interactions with simvastatin (see section 5.2: Concomitant drugs, not allowed and allowed).\n14. Patients with a history of significant extrahepatic disease with poor short-term prognosis, including New York Heart Association Grade III \u002F V congestive heart failure, GOLD COPD\\> 2, chronic kidney disease with serum creatinine\\> 2mg \u002F dL or under therapy of kidney replacement.\n15. Patients with extrahepatic malignancies, including solid tumors and hematologic malignancies.\n16. Patients with a history or increased risk of intestinal obstruction.\n17. Pregnancy or breastfeeding.\n18. Patients included in other clinical trials during the previous month.\n19. Patients with mental disabilities, language barriers, poor social support or any other reason considered by the researcher as essential for adequate understanding, cooperation or compliance with the study.\n20. Presence of data on alcoholic hepatitis in liver biopsy upon inclusion.\n21. Patients with contraindications for statins.\n22. Known hypersensitivity to simvastatin.\n23. Refusal to sign the informed consent",{"count":400,"type":21},90,[232,402],"PHASE3","Evaluate the efficacy of simvastatin in reducing liver fibrosis in patients with advanced fibrosis due to alcohol",[405,25],"Liver Fibrosis","2024-12-03",{"date":408,"type":39},"2024-12-04",{"date":410,"type":39},"2022-02-22",{"date":412,"type":21},"2027-12",{"name":414,"class":46},"Anna Cruceta",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":18,"enrollmentInfo":422,"targetDuration":4,"studyType":58,"phases":424,"briefSummary":425,"conditions":426,"keywords":432,"overallStatus":349,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":47},"100570683","phase-2-a-study-of-the-safety-and-exploratory-efficacy-of-oral-afa-281-in-patients-with-alcohol-use-disorder-100570683","NCT06710431","A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder","A Double-blind, Placebo-controlled, Phase IIA Human Laboratory Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder","Inclusion Criteria:\n\n1. Age between 21 and 65\n2. Must voluntarily sign and date each informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.\n3. Meet current (i.e., past 12 months) DSM-5 diagnostic criteria for moderate or severe AUD\n4. Report drinking at least 28 drinks per week if male, 21 drinks per week if female, in the 28 days prior to consent.\n5. Must be surgically sterile (vasectomy, tubal ligation, or hysterectomy) or agree to be sexually inactive or agree to use a barrier method of birth control (i.e., condom) from the start of screening until study completion, and agree to refrain from donating sperm for 90 days after study drug administration.\n\nExclusion Criteria:\n\n1. Current treatment for alcohol use or a history of treatment in the 30 days before enrollment or treatment seeking\n2. Current (last 12 months) DSM-5 diagnosis of dependence on any psychoactive substances other than nicotine\n3. Current DSM-5 diagnosis of substance use disorder for any substance other than alcohol and nicotine\n4. Lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder\n5. Current DSM-5 major depressive disorder with suicidal ideation\n6. Positive urine screen for narcotics, amphetamines, or sedative hypnotics\n7. Clinically significant alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised\n8. Pregnancy, nursing, or refusal to use reliable method of birth control if female\n9. History of significant sensitivity to any drug.\n10. Has a clinically significant abnormal ECG or an ECG with a QTc interval corrected for heart rate using the Fridericia formula (QTcF) \\> 430 ms.\n11. History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, endocrine, dermatological, metabolic or psychiatric disease or disorder, or any uncontrolled medical illness.\n12. Has an estimated creatinine clearance (CrCl) outside of normal range.\n13. History of head trauma with loss of consciousness, seizures or convulsions, including febrile, alcohol or drug withdrawal seizures.\n14. History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH, or absorption.\n15. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab). Negative HIV status will be confirmed at Screening and the results will be maintained confidentially by the study site.\n16. Liver enzymes AST, ALT, or GGT ≥ 3 times upper normal limit.\n17. Positive urine drug screen for drugs of abuse at Screening or Day -1.\n18. Receipt of any drug by injection within 30 days prior to study drug administration.\n19. A clinically notable vital sign abnormality including a history of syncopal or near syncopal events following abrupt change in posture.\n20. Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration.\n21. Pregnant or nursing women.\n22. Receipt of any investigational products within 6 weeks prior to study drug administration.\n23. Current enrollment in another clinical study.\n24. Previous enrollment in this study.\n25. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to participate in the AFA-281 Phase I1a Study.",{"count":423,"type":21},36,[232],"This study will evaluate the safety and exploratory efficacy of AFA-281 in patients with Alcohol use disorder on cravings, subjective response to alcohol, pain thresholds, anxiety, depression, and sleep.",[25,427,428,429,430,431],"Alcohol Abuse\u002Faddiction","Anxiety","Pain Threshold","Depression Disorders","Sleep Disorder",[433,69,208,434,435,436,437],"AFA-281","depression","pain threshold","sleep disorder","anxiety","2024-11-26",{"date":440,"type":39},"2024-11-29",{"date":442,"type":21},"2025-10-01",{"date":81,"type":21},{"name":445,"class":83},"Afasci Inc",{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":47},"100232150","effect-of-alcohol-and-drugs-of-abuse-on-immune-function-in-critically-ill-patients-with-respiratory-failure-100232150","NCT02299921","Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure","Inclusion criteria:\n\n* Specific Aim 1: Adult medical ICU patients admitted to the University of Colorado Hospital for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs\n* Specific Aim 2: (1) Adult medical ICU patients with respiratory failure (due to underlying lung pathology) and who require endotracheal intubation and mechanical ventilation. (2) Adult medical and other ICU patients with respiratory failure, not related to a lung condition, and who require endotracheal intubation and mechanical ventilation. (3) Adult ICU patients previously admitted to the University of Colorado Hospital for a primary respiratory problem, and who required care ≥48 hrs.\n\nExclusion criteria, Specific Aim 1 and 2:\n\n* Patients who are expected to require ICU care \\\u003C48 hrs\n* Patients admitted to the ICU who are not ICU status (being housed for space issues)\n* Patient is unlikely to survive 48 hours\n* Patient is on comfort care (hospice measures)\n* Patients less than 18 or greater than 90 years of age\n* Patient is a prisoner\n* ICU attending declines enrollment of patient\n* Patients who are pregnant\n* Patients who have significant anemia, defined as Hgb\\\u003C8% or Hct\\\u003C24%, or who have evidence of active bleeding.\n\nFor bronchoscopy portion of Specific Aim 2.\n\n* Patients who are on either a fraction of inspired oxygen inspired oxygen fraction (FiO2)\\>80% or positive end expiratory pressure (PEEP) \\>10 cm H20\n* Patients with platelets less than 30,000(chronically)\n* Patients who are expected to undergo a spontaneous breathing trial within the next 4 hours\n* Patients with an order or plan to extubate in the next 4 hours\n* Patients who have an endotracheal tube (ETT) \\\u003C7.5 F\n* Patients who are currently dangerously agitated\n* Pregnant women\n\nExclusion criteria (outpatients ONLY for SA2 (3)):\n\n1. Patients who required ICU care \\\u003C48 hrs\n2. Patients less than 18 or greater than 90 years of age\n3. Patient is a prisoner\n4. Patients who are pregnant\n5. Residency \\> 40 miles from UCH clinics\n6. non-English or non-Spanish speaking\n7. Inability to perform study procedures (i.e. physical disability)\n8. unable to perform pulmonary function testing\n9. diagnosis of chronic pulmonary disease (e.g. COPD)\n10. diagnosis of chronic neurodegenerative disease or severe dementia\n11. history of anoxic or traumatic brain injury\n12. prior ICU hospitalization at a non-UCH facility.","90 Years",{"count":454,"type":21},300,"This study plans to learn more about people who are sick in the hospital with a lung infection, or respiratory failure. Respiratory failure, or severe lung failure, is a life-threatening disease. When it happens, the lungs have trouble carrying out their normal function of getting oxygen into the blood, and removing carbon dioxide from the body. Investigators are conducting this study to see what drinking too much alcohol, using tobacco products, or using drugs (both legal and illegal) may do to lung infections and respiratory failure.\n\nSubjects are asked to be in this research study because they are thought to have a lung infection and may also have respiratory failure. Alcohol, tobacco, and drug use have been linked to lung infections, respiratory failure, and even death, but the reasons for this aren't known. People who use unhealthy amounts of alcohol, tobacco, and or drugs may be more at risk for lung infections, and for severe complications due to lung infection. Subject participation is important whether or not you use alcohol and or drugs.",[457,25,458,459],"Infection","Drugs of Abuse","Lung Injury","2024-10-07",{"date":462,"type":39},"2024-10-08",{"date":464,"type":39},"2014-11",{"date":466,"type":21},"2029-04-30",{"name":468,"class":46},"University of Colorado, Denver",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":177,"sex":16,"minAge":332,"maxAge":18,"enrollmentInfo":476,"targetDuration":4,"studyType":58,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":47},"100562776","effectiveness-and-safety-of-probiotics-in-protecting-liver-function-100562776","NCT06607562","Effectiveness and Safety of Probiotics in Protecting Liver Function","Protective Effect of Probiotics BC99 on Liver Function in Long-Term Alcohol Consumers: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. A history of long-term heavy alcohol consumption, equivalent to ethanol intake ≥40g\u002Fday for over 1 year. The conversion formula is: ethanol (g) = volume of ethanol-containing beverage (mL) × ethanol content (%) × 0.8 (specific gravity of ethanol);\n2. Body Mass Index (BMI) between 18kg\u002Fm² and 25kg\u002Fm²;\n3. Voluntarily signed a written informed consent form, agreeing to participate in this study;\n4. Agreed to comply with the study protocol and restrictions;\n5. Subjects (including male participants) have no plans for conception from 14 days prior to screening until 6 months after the end of the trial and voluntarily agree to use effective contraception.\n\nExclusion Criteria:\n\n1. Patients with various types of viral hepatitis, autoimmune liver disease, drug-induced liver damage, vascular liver disease, genetic metabolic liver disease, or primary liver cancer;\n2. Individuals who have recently consumed substances with similar functions to the tested product, potentially affecting the study results;\n3. Patients with severe allergies or immune deficiencies;\n4. Pregnant, breastfeeding, or women with plans for pregnancy;\n5. Individuals with severe diseases of vital organs such as cardiovascular, pulmonary, hepatic, renal conditions, or those with diabetes, severe thyroid disorders, metabolic diseases, malignant tumors, or severe immune system disorders;\n6. Individuals who have used antibiotics within the past two weeks;\n7. Participants who did not comply with the required consumption of the tested product or missed follow-ups, making it impossible to evaluate the effectiveness;\n8. Other participants deemed unsuitable by the researchers.",{"count":230,"type":21},[60],"To evaluate the effectiveness and safety of using probiotics to protect the liver function of long-term alcohol consumers",[25],"2024-09-18",{"date":482,"type":39},"2024-09-23",{"date":484,"type":39},"2024-06-03",{"date":486,"type":21},"2025-04-15",{"name":488,"class":83},"Wecare Probiotics Co., Ltd.",{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":177,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":58,"phases":498,"briefSummary":500,"conditions":501,"keywords":502,"overallStatus":349,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":47},"100560915","phase-1-motivational-interviewing-intervention-for-risky-drinking-treatment-among-indigenous-population-100560915","NCT06583356","Motivational Interviewing Intervention For Risky Drinking Treatment Among Indigenous Population","The Adaptation and Effectiveness of Motivational Interviewing Intervention For Risky Drinking Treatment Among Indigenous Population: Protocol For A Single-arm Trial","MIRDIP","Phase 1 (validation of translated questionnaires)\n\nInclusion Criteria:\n\n* Individuals in the selected settlement age ≥ 18 years old who are current drinkers, irrespective of volume (current drinker is defined as individual who has consumed any alcoholic beverage in the past 12 months)\n* Agrees to participate in the study after explanation given\n\nExclusion Criteria:\n\n* Those with history of serious mental illness or cognitive impairment\n* Those who are unable to speak proficient Malay or Jakun language\n\nPhase 2 (single-arm trial):\n\nInclusion Criteria:\n\n* Individuals in the selected settlement and its surrounding, age ≥ 18 years old who are current drinkers\n* Agrees to participate in the study after explanation given\n\nExclusion Criteria:\n\n* AUDIT-10 score \\\u003C 8 or \\> 19\n* Those with history of serious mental illness or cognitive impairment\n* Those who are currently on other alcohol intervention programmes\n* Those who are unable to speak proficient Malay or English language",{"count":423,"type":21},[499,232],"PHASE1","The goal of this single-arm trial is to adapt and evaluate the effectiveness of motivational interviewing intervention for treating risky drinking behaviour among indigenous population in Pahang, Malaysia.\n\nTo achieve this, the investigators will:\n\ni) Translate 3 questionnaires regarding alcohol consumption from English into Jakun language (a language of one of Malaysia\\'s indigenous communities) ii) Adapt a motivational interviewing intervention for treatment of risky drinking for this community iii) Implement the intervention and measure its outcomes using the translated questionnaires\n\nParticipants will:\n\ni) Answer translated questionnaires during the validation of questionnaires (phase 1) ii) Receive 3 sessions of motivational interviewing (phase 2)",[25],[503],"motivational interviewing, risky drinking","2024-09-01",{"date":506,"type":39},"2024-09-04",{"date":508,"type":21},"2024-10-01",{"date":510,"type":21},"2025-05-31",{"name":512,"class":46},"Department of Public Health Medicine, MARA University of Technology",{"id":514,"slug":515,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":58,"phases":522,"briefSummary":523,"conditions":524,"keywords":525,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":47},"100548059","a-mobile-intervention-for-black-individuals-who-engage-in-hazardous-drinking-100548059","NCT06416059","A Mobile Intervention for Black Individuals Who Engage in Hazardous Drinking","A Mobile-Delivered Personalized Feedback Intervention for Black Individuals Who Engage in Hazardous Drinking","Inclusion Criteria:\n\n* Being 21 years of age or older\n* Self-identifying as Black or African American\n* Meeting criteria for current hazardous drinking pattern\n* Meeting criteria for clinical anxiety\n* Being able to provide written, informed consent\n* Owning a smartphone.\n\nExclusion Criteria:\n\n* Current participation in alcohol or other substance abuse treatment\n* Engaged in psychotherapy for anxiety or depression\n* Concurrent use of medication for anxiety or depression\n* Being pregnant by self-report\n* Residence outside of the United States confirmed via survey geolocation\n* Inability to provide a valid United States-issued driver's license or identification card to verify identity.",{"count":521,"type":21},50,[60],"The purpose of this study is to develop and examine a culturally adapted, mobile health application for the Android and iOS platform. The application uses a personalized feedback intervention (PFI) designed to enhance knowledge regarding adverse anxiety-alcohol interrelations, increase motivation and intention to reduce hazardous drinking, and reduce positive attitudes and intention regarding anxiety-related alcohol use among Black hazardous drinkers with clinical anxiety.",[25,428],[526,527,528],"African American","Black","Personalized Feedback Intervention","2024-06-12",{"date":531,"type":39},"2024-06-17",{"date":533,"type":39},"2023-05-15",{"date":535,"type":21},"2024-08-31",{"name":537,"class":46},"University of Houston",{"id":539,"slug":540,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":255,"enrollmentInfo":545,"targetDuration":4,"studyType":58,"phases":547,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":47},"100458175","personalized-feedback-intervention-for-latinx-drinkers-with-anxiety-100458175","NCT05246202","Personalized Feedback Intervention for Latinx Drinkers With Anxiety","Latinx Hazardous Drinkers With Clinical Anxiety: Effectiveness Trial of a Personalized Normative Feedback Intervention","Inclusion Criteria:\n\n* Being between the age of 21 to 75 years of age\n* Being self-identified as Latinx or Hispanic\n* Fluent in Spanish\n* Meeting criteria for current hazardous drinking pattern\n* Meeting criteria for clinical anxiety\n* Being able to provide written, informed consent\n\nExclusion Criteria:\n\n* Being involved in alcohol or other substance use program\n* Currently pregnant\n* Current engagement in psychotherapy for anxiety",{"count":546,"type":21},250,[60],"The purpose of this study is to develop, evaluate the acceptability\u002Ffeasibility (Phase IA), and test (Phase IB) the effectiveness of a brief, integrated, single-session, computer-based, culturally adapted personalized feedback intervention (PFI) designed to enhance knowledge regarding adverse anxiety-alcohol interrelations, increase motivation and intention to reduce hazardous drinking, and reduce positive attitudes and intention regarding anxiety-related alcohol use among Latinx hazardous drinkers with anxiety.",[25,428],[551,552,528],"Latinx","Hispanic","2024-06-06",{"date":555,"type":39},"2024-06-07",{"date":557,"type":39},"2022-09-30",{"date":559,"type":21},"2026-05-31",{"name":537,"class":46},{"id":562,"slug":563,"hasResults":11,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":58,"phases":571,"briefSummary":572,"conditions":573,"keywords":577,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":590},"100504953","the-liver-care-trial-100504953","NCT05855031","The Liver Care Trial","The Liver Care Trial: Screening for Liver Disease in Individuals Attending Treatment for Alcohol Use Disorder - a Randomized Controlled Study","Inclusion Criteria:\n\n* Attending outpatient treatment for alcohol use disorder (international classification of disease version 10: F102: alcohol dependence or F101: harmful alcohol use) at Novavi Køge or Novavi Roskilde\n* Informed written consent\n\nExclusion Criteria:\n\n* Not speaking Danish or English\n* Severe liver disease (known by the participant)","110 Years",{"count":570,"type":21},408,[60],"The goal of this clinical trial is to evaluate the efficacy of screening for liver disease with liver stiffness measurement on abstinence or light consumption after 6 months in individuals who are receiving treatment for alcohol use disorder and without a history of liver disease. The investigators will conduct a randomized controlled trial with concealed allocation comparing A) an invitation to a liver stiffness measurement, blood sampling and leaflet on alcohol-related disease (intervention) with B) an invitation to blood sampling (control). The primary outcome is 'abstinence or light consumption' (≤ 10 units\u002Fweek) throughout the last months, and assessed 6 months after randomization.",[574,26,25,63,575,576],"Alcoholic Liver Disease","Fibrosis, Liver","Alcohol-Related Disorders",[578,579,580,581],"Screening","Fibroscan","Liver stiffness measurement","abstinence",{"date":583,"type":39},"2023-05-17",{"date":585,"type":39},"2023-05-08",{"date":587,"type":21},"2027-05-01",{"name":589,"class":46},"Zealand University Hospital",2,{"id":592,"slug":593,"hasResults":11,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":598,"targetDuration":4,"studyType":58,"phases":600,"briefSummary":601,"conditions":602,"keywords":605,"overallStatus":349,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":616,"locationsCount":4},"100431377","neurobiological-effects-of-transcranial-direct-current-stimulation-treatment-in-alcohol-use-disorder-100431377","NCT04897295","Neurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use Disorder","Neurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use Disorder: a Sham-controlled Trial.","Inclusion Criteria:\n\n* diagnosis of Alcohol Use Disorder (at least 12 months);\n* drug free\u002Fstable psychopharmacological therapy (one month), with the exception of guidelines treatments for alcoholic abstinence (treatment-as-usual);\n* any assumption of substances for at least 48 hours.\n\nExclusion Criteria:\n\n* presence of organic pathologies (capable of interfering with the safety of the procedure) in comorbidities;\n* presence of intellectual disability;\n* history of epileptic seizures (also in first degree relatives);\n* score\\> 12 on the Young Mania Rating Scale (Y-MRS).",{"count":599,"type":21},30,[60],"Background: Alcohol Use Disorder (AUD) is a complex psychiatric disorder, involving several brain areas and neurocircuits. Transcranial Direct Current Stimulation (tDCS) allows to stimulate superficial areas of brain using a weak electrical current. Preliminary data suggest that tDCS may reduce alcohol craving and consumption.\n\nObjectives: The main outcome is to test if tDCS can reduce alcohol craving and use and to assess the changes in BDNF and pro-BDNF levels. Secondary outcomes are the assessment of other psychiatric dimensions (mood, behavioral and cognitive alterations) associated with prolonged alcohol use.\n\nEligibility: Healthy, right-handed adults ages 18-65 who do have AUD (moderate to severe).\n\nDesign: This is a randomized, double-blind, sham-controlled study with three phases: 1) a tDCS intensive treatment phase; 2) follow-up with weekly tDCS stimulation; 3) follow-up without tDCS stimulation.\n\nParticipants will be screened with:\n\n* Psychometric Scales\n* Medical history\n* Physical exam\n* Urine tests and breathalyzer\n* After being enrolled, baseline behavioral and laboratory data will be collected. In particular, participants will undergo:\n* Psychometric Scales\n* Venous blood sample (BDNF\u002FproBDNF levels)\n\nParticipants will be randomized to real or sham tDCS arm. The stimulation will be delivered daily for five days during the first week (intensive treatment phase) and then weekly for 3 months (follow-up with stimulation). During this period patient will be tested with a behavioral and psychometric evaluation.Therefore, participants will receive 3 follow-up monthly visits without tDCS stimulation, in which behavioral and psychometric data will be collected.\n\nTreatment includes:\n\n* tDCS: The tDCS will be delivered with a stimulator connected to two sponge electrodes, soaked in a saline solution. The stimulation will be administered at a current intensity of approximately 1 mA, for the duration of 20 minutes. The anode will be placed on the right DLPFC, the cathode on the contralateral cortical area.\n* BDNF\u002FproBDNF levels: A venous blood sample will be collected before the first stimulation and after the last stimulation of the intensive-stimulation period (first week). The blood sample will be centrifuged within 20 minutes of sampling at 1000 × g for 15 minutes. Then, the serum will be aliquoted and stored at -80 ° C until analysis.\n* Repeat of screening tests and questionnaires\n* Urine toxicological screen and breathalyzer",[603,25,64,576,342,27,604],"Alcohol Use Disorder (AUD)","Mental Disorder",[26,606,607,372,608,609],"transcranial Direct Current Stimulation","Non-Invasive Brain Stimulation","Brain Derived Neurotrophic Factor","Pro-Brain Derived Neurotrophic Factor","2021-10-25",{"date":612,"type":39},"2021-10-26",{"date":614,"type":21},"2021-12-01",{"date":356,"type":21},{"name":617,"class":46},"ITAB - Institute for Advanced Biomedical Technologies"]